Diagnosis and stratification of systemic AL amyloidosis in the light of the 2013 Czech Myeloma Group recommendation
Authors:
V. Ščudla 1; T. Pika 1; P. Látalová 2; P. Flodr 2; V. Maisnar 3; R. Hájek 4; Česká Myelomová Skupina
Authors‘ workplace:
III. interní klinika-revmatologická, nefrologická a endokrinologická LF UP a FN, Olomouc
1; Ústav klinické a molekulární patologie LF UP a FN, Olomouc
2; IV. Interní hematologická klinika LF UK a FN, Hradec Králové
3; Klinika hematoonkologie LF OU a FN, Ostrava
4
Published in:
Klin. Biochem. Metab., 22 (43), 2014, No. 2, p. 49-60
Overview
The paper is concerned with classification of amyloidosis and presenting clinical manifestations, examination methods and an effective diagnostic algorithm related to systemic AL amyloidosis. Greater attention is paid to current investigation techniques and their role in the differential diagnosis and stratification of systemic AL amyloidosis as a starting point for prognostic prediction and individual selection of therapy. The review has been prepared in the light of the 2013 Czech Myeloma Group recommendations “Diagnosis and Treatment of Systemic AL Amyloidosis”.
Key words:
classification of amyloidosis, systemic AL amyloidosis, diagnostic algorithm, differential diagnosis, prognostic stratification.
Sources
1. Kyle, R. A., Gertz, M. A. Primary systemic amyloidosis: clinical features in 474 and laboratory cases. Semin. Hematol. 1995, 32, p. 45-59.
2. Sipe, J. D., Benson, M. D., Buxbaum, J. N. et al. Amyloid fibril protein nomenclature: 2012 recommendation from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2012, 19, p. 167-70.
3. Kyle, R. A., Linos, A., Beard, C. M. et al. Incidence and natural history of primary systemic amyloidosis in Olmsted county, Minessota,1950 through 1989. Blood 1992, 79, p. 1817-22.
4. Ryšavá, R. Systémové amyloidózy a jejich léčba. Maxdorf Jessenius/Sv 61, Praha 2013, p. 124.
5. Gertz, M. A. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 2011, 86, p. 181-86.
6. Bird, J. Guidelines on the diagnosis and management of AL amyloidosis. Br. J. Haematol. 2004, 125, p. 681-700. www.blackwellpublishing.com/bjh; www.bloodmed.com;7. Ščudla, V., Pika, T. Současné možnosti diagnostiky a léčby systémové AL-amyloidózy. Vnitř. Lék. 2009, 55 (Suppl 1), p. 77-87.
8. Rajkumar, S. V., Glassock, R. J., Kyle, R. A. et al. Pathogenesis and clinical features of primary (AL) amyloidosis and light and heavy chain deposition diseases. www.uptodate.com
9. Merlini, G. AL amyloidosis: diagnosis and prognosis. Haematologica 2007, 92(Suppl 2), p. 58-59.
10. Lavatelli, F., Palladini, G., Merlini, G. Pathogenesis of systemic amyloidosis. In: Gertz MA, Rajkumar SV. Amyloidosis: diagnosis and treatment, 1st ed., Springer Science, New York 2010, p. 49-64.
11. Comenzo, R. L., Wally, J., Kica, G. et al. Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloidrelated organ involvement and survival after stem cell transplantation. Br. J. Haematol. 1999, 106, p. 744-51.
12. Harrison, C. J., Mazzullo, H., Ross, F. M. et al. Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. Br. J. Haematol. 2002, 117, p. 427-35.
13. Rajkumar, S. V., Glassock, R., Kyle, R. A. Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis (primary amyloidosis). Available from: www.uptodate.com, 2013 UpToDate
14. Adam, Z., Ščudla, V. Klinické projevy a diagnostika AL amyloidózy a některých dalších typů amyloidóz. Vnitř. Lék. 2001, 47, p. 36-45.
15. Gertz, M. A., Hayman, S. R. Immunoglobulin light chain amyloidosis. In: Rajkumar SV, Kyle RA. Treatment of multiple myeloma and related disorders. Cambridge: Cambridge University Press, 2009, p. 112-128.
16. Krejčí, K., Zadražil, J., Tichý, T. Nefropatie v ultrazvukovém a histologickém obraze. 1. vyd., Praha 2011, Maxdorf. Jessenius, p. 186.
17. Pika, T., Vymětal, J., Metelka, R. et al. Postižení srdce při AL amyloidóze. Interní Med. 2008, 10, p. 466-69.
18. Fikrle, M., Paleček, T., Kuchyňka, P. et al. Cardiac amyloidosis: A comprehensive review. Cor et Vasa 2012, http://dx.doi.org/10.1016/j.crvasa.2012.11.018.
19. Gertz, M. A., Comenzo, R., Falk, R. H. et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International symposium on amyloid and amyloidosis. Am. J. Hematol. 2005, 79, p. 319- 28.
20. Bradwell, A. R. Serum free light chain analysis (plus Hevylite) 6th ed., Birmingham: The Binding Site Ltd, 2010, p. 350.
21. Howie, A. J., Brewer, D. B., Howell, D. et al. Physical basis of colors seen in Congo red-stained amyloid in polarized light. Lab. Invest. 2008, 88, p. 232-42.
22. Picken, M. M., Westermark, P. Amyloid detection and typing: summary of current practice and recommendations of the consensus group. Amyloid. 2011, 18 (Suppl. 1), p. 48-50. doi: 10.3109/13506129.2011.574354017.
23. Schönland, S. O., Hegenbart, U., Bochtler, T. et al. Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 2012, 119, p. 488-93.
24. Marcus, A., Sadimin, E., Richardson, M., et al. Fluorescence microscopy is superior to polarized microscopy for detecting amyloid deposits in Congo red-stained trephine bone marrow biopsy specimens. Am. J. Clin. Pathol. 2012, 138, p. 590-93.
25. Arbustini, E., Verga, L., Concardi, M. et al. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid 2002, 9, p. 108-14.
26. Maisnar, V., Tichý, M. a kol. Monoklonální imunoglobuliny – výskyt, význam a možnosti jejich průkazu. 1.vyd., Nucleus, Hradec Králové 2012, p. 125.
27. Vávrová, J., Tichý, M., Maisnar, V. et al. Stanovení volných lehkých řetězců a Hevylite u monoklonálních gamapatií. In: Maisnar V, Tichý M, a kol. Monoklonální imunoglobuliny – výskyt, význam a možnosti jejich průkazu. 1. vyd., Nucleus, Hradec Králové 2012, p. 55- 60.
28. Katzmann, J. A., Abraham, R. S., Dispenzieri, A. et al. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin. Chem. 2005, 51, p. 878-81.
29. Palladini, G., Perlini, S., Merlini, G. Imaging of systemic amyloidosis. In: Gertz MA, Rajkumar SV: Amyloidosis: diagnosis and treatment. Springer Science and Business Media, LLC 2010, p. 15- 32.
30. Kumar, S., Dispenzieri, A., Lacy, M. Q. et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J. Clin. Oncol. 2012, 30, p. 989- 95.
31. Wechalekar, A., Faint, J., Bradwell, S. et al. Significance of abnormal serum immunoglobulin heavy/light chain ratios (Hevylite) in 294 patients with systemic AL amyloidosis. Haematologica 2011, 96, p. 392-98.
32. Piper, C., Butz, T., Farr, M. et al. How to diagnose cardiac amyloidosis early: impact of ECG, tissue doppler echocardiography, and myocardial biopsy. Amyloid 2010, 17, p. 1-9.
33. Kovářová, L., Varmužová, T., Žarbochová, P. et al. Flow cytometry in monoclonal gammopathies. Klin. Onkol. 2011, 24, p.24-29.
34. Dispenzieri, A., Gertz, M. A., Kyle, R. A. et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J. Clin. Oncol. 2004, 22, p. 3751-57.
35. Dispenzieri, A. Assessing response and prognosis in AL amyloidosis. In. Gertz MA, Rajkumar SV. Amyloidosis: diagnosis and treatment, 1st ed. Springer Science, New York 2010, p. 77-93.
36. Merlini, G., Wechalekar, D., Palladini, G. Systemic light chain amyloidosis: an update for treating physicians. Blood 2013, 121, p. 5124-5130.
37. Paiva, B., Vídriales, M. B., Pérez, J. J. et al. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis. Blood 2011, 117, p. 3613-16.
38. Wechalekar, A.D., Offer, M., Gillmore, J. D. et al. Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation. Nat. Clin. Pract. Cardiovasc. Med. 2009, 6, p. 128-33.
39. Leung, N., Bridoux, F., Hutchison, C. A. et al. Monoclonal gammopathy of renal significance (MGRS): when MGUS is no longer undetermined or insignificant. Doi: 10.1182/blood-2012-07-445304;
40. Ščudla, V., Minařík, J., Pika, T. Nemoc z ukládání lehkých řetězců imunoglobulinu (light chain deposition disease). Vnitř. Lék. 2012, 58, p. 38-43.
41. Dinner, S., Witteles, W., Witteles, R. et al. The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. Br. J. Haematol. 2013, 161, p. 367-72.42. Ščudla, V., Adam, Z., Hájek, R. et al.: Diagnostika a léčba systémové AL amyloidózy. Doporučení České myelomové skupiny 2013. Transfuze Hematol. dnes 2013, 19, p. 3-52.
Labels
Clinical biochemistry Nuclear medicine Nutritive therapistArticle was published in
Clinical Biochemistry and Metabolism
2014 Issue 2
Most read in this issue
- Clinical Problems of IgM Monoclonal Gammapathies
- Risk factors of Asymptomatic (Smoldering) Multiple Myeloma
- The Standard of Analytical Quality of Glucometers
- Diagnosis and stratification of systemic AL amyloidosis in the light of the 2013 Czech Myeloma Group recommendation